HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kwekkeboom, D. J. Articles by Krenning, E. P. Search for Related Content PubMed PubMed Citation Articles by Kwekkeboom, D. J. Articles by Krenning, E. P.

Overview of Results of Peptide Receptor Radionuclide Therapy with 3 Radiolabeled Somatostatin Analogs

¹ Department of Nuclear Medicine, Erasmus Medical Center, University Hospital Rotterdam, Rotterdam, The Netherlands
² Department of Nuclear Medicine, University Hospital Basel, Basel, Switzerland
³ Department of Nuclear Medicine, European Institute of Oncology, Milan, Italy
⁴ Division of Hematology and Oncology, Department of Medicine, Louisiana State University Health Sciences Center, New Orleans, Louisiana
⁵ Department of Nuclear Medicine, Universitaire Catholique Louvain, Brussels, Belgium
⁶ Lee Moffitt Cancer Center, University of South Florida, Tampa, Florida
⁷ Division of Endocrinology, Department of Internal Medicine, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, Iowa

A new treatment modality for inoperable or metastasized gastroenteropancreatic tumors is the use of radiolabeled somatostatin analogs. Initial studies with high doses of [¹¹¹In-diethylenetriaminepentaacetic acid (DTPA)⁰]octreotide in patients with metastasized neuroendocrine tumors were encouraging, although partial remissions were uncommon. Another radiolabeled somatostatin analog that is used for peptide receptor radionuclide therapy (PRRT) is [⁹⁰Y-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)⁰,Tyr³]octreotide. Various phase 1 and phase 2 PRRT trials have been performed with this compound. Despite differences in the protocols used, complete and partial remissions in most of the studies with [⁹⁰Y-DOTA⁰,Tyr³]octreotide were in the same ranges, 10%–30%; these ranges were higher than those obtained with [¹¹¹In-DTPA⁰]octreotide. Treatment with the newest radiolabeled somatostatin analog, [¹⁷⁷Lu-DOTA⁰,Tyr³]octreotate, which has a higher affinity for the subtype 2 somatostatin receptor, resulted in complete or partial remissions in 30% of 76 patients. Tumor regression was positively correlated with a high level of uptake on OctreoScan imaging, a limited hepatic tumor mass, and a high Karnofsky performance score. Treatment with radiolabeled somatostatin analogs is a promising new tool in the management of patients with inoperable or metastasized neuroendocrine tumors. Symptomatic improvement may occur with all ¹¹¹In-, ⁹⁰Y-, or ¹⁷⁷Lu-labeled somatostatin analogs that have been used for PRRT. The results obtained with [⁹⁰Y-DOTA⁰,Tyr³]octreotide and [¹⁷⁷Lu-DOTA⁰,Tyr³]octreotate are very encouraging in terms of tumor regression. Also, if kidney protective agents are used, the side effects of this therapy are few and mild, and the duration of the therapy response for both radiopharmaceuticals is more than 2 y. These data compare favorably with those for the limited number of alternative treatment approaches.

Key Words: somatostatin • somatostatin receptor • radionuclide therapy • gastroenteropancreatic tumors

This article has been cited by other articles:

				D. J Kwekkeboom, B. L Kam, M. van Essen, J. J M Teunissen, C. H J van Eijck, R. Valkema, M. de Jong, W. W de Herder, and E. P Krenning Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors Endocr. Relat. Cancer, January 29, 2010; 17(1): R53 - R73. [Abstract] [Full Text] [PDF]

				I. Kayani, B. G. Conry, A. M. Groves, T. Win, J. Dickson, M. Caplin, and J. B. Bomanji A Comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in Pulmonary Neuroendocrine Tumors J. Nucl. Med., December 1, 2009; 50(12): 1927 - 1932. [Abstract] [Full Text] [PDF]

				E. Andersson, C. Sward, G. Stenman, H. Ahlman, and O. Nilsson High-resolution genomic profiling reveals gain of chromosome 14 as a predictor of poor outcome in ileal carcinoids Endocr. Relat. Cancer, September 1, 2009; 16(3): 953 - 966. [Abstract] [Full Text] [PDF]

				D. Bushnell Treatment of Metastatic Carcinoid Tumors With Radiolabeled Biologic Molecules J Natl Compr Canc Netw, July 1, 2009; 7(7): 760 - 764. [Abstract] [PDF]

				D. A. Mankoff, J. M. Link, H. M. Linden, L. Sundararajan, and K. A. Krohn Tumor Receptor Imaging J. Nucl. Med., June 1, 2008; 49(Suppl_2): 149S - 163S. [Abstract] [Full Text] [PDF]

				G. Khanna, D. Bushnell, and M. S. O'Dorisio Utility of Radiolabeled Somatostatin Receptor Analogues for Staging/Restaging and Treatment of Somatostatin Receptor-Positive Pediatric Tumors Oncologist, April 1, 2008; 13(4): 382 - 389. [Abstract] [Full Text] [PDF]

				W. J. G. Oyen, L. Bodei, F. Giammarile, H. R. Maecke, J. Tennvall, M. Luster, and B. Brans Targeted therapy in nuclear medicine current status and future prospects Ann. Onc., November 1, 2007; 18(11): 1782 - 1792. [Abstract] [Full Text] [PDF]

				M. Cremonesi, M. Ferrari, L. Bodei, G. Tosi, and G. Paganelli Dosimetry in Peptide Radionuclide Receptor Therapy: A Review J. Nucl. Med., September 1, 2006; 47(9): 1467 - 1475. [Abstract] [Full Text] [PDF]

				E. Vegt, J. F.M. Wetzels, F. G.M. Russel, R. Masereeuw, O. C. Boerman, J. E. van Eerd, F. H.M. Corstens, and W. J.G. Oyen Renal Uptake of Radiolabeled Octreotide in Human Subjects Is Efficiently Inhibited by Succinylated Gelatin J. Nucl. Med., March 1, 2006; 47(3): 432 - 436. [Abstract] [Full Text] [PDF]

				G A Kaltsas, D Papadogias, P Makras, and A B Grossman Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues Endocr. Relat. Cancer, December 1, 2005; 12(4): 683 - 699. [Abstract] [Full Text] [PDF]

				R. Valkema, S. A. Pauwels, L. K. Kvols, D. J. Kwekkeboom, F. Jamar, M. de Jong, R. Barone, S. Walrand, P. P.M. Kooij, W. H. Bakker, et al. Long-Term Follow-Up of Renal Function After Peptide Receptor Radiation Therapy with 90Y-DOTA0,Tyr3-Octreotide and 177Lu-DOTA0, Tyr3-Octreotate J. Nucl. Med., January 1, 2005; 46(1_suppl): 83S - 91S. [Abstract] [Full Text] [PDF]

				R. Barone, F. Borson-Chazot, R. Valkema, S. Walrand, F. Chauvin, L. Gogou, L. K. Kvols, E. P. Krenning, F. Jamar, and S. Pauwels Patient-Specific Dosimetry in Predicting Renal Toxicity with 90Y-DOTATOC: Relevance of Kidney Volume and Dose Rate in Finding a Dose-Effect Relationship J. Nucl. Med., January 1, 2005; 46(1_suppl): 99S - 106S. [Abstract] [Full Text] [PDF]